Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Chiome Bioscience Inc. ( (JP:4583) ).
Chiome Bioscience reported non-consolidated net sales of ¥147 million for the first quarter ended March 31, 2026, a 6.1% year-on-year increase, while trimming its net loss to ¥233 million as operating and ordinary losses narrowed. Total assets fell slightly to ¥1,670 million, but equity and the equity ratio improved markedly to 78.0%, aided in part by an increase in shares issued despite the continued absence of dividends.
The company maintained its policy of not forecasting results for its inherently uncertain drug discovery and development operations, reiterating guidance only for its drug discovery support business with expected annual sales of ¥600 million. With no change to its overall earnings outlook and ongoing losses despite modest revenue growth, Chiome remains in an early-stage, investment-heavy phase that underscores both its financial fragility and its reliance on future R&D milestones to unlock shareholder value.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange that operates drug discovery and development alongside a drug discovery support business. The company focuses on generating antibody-based therapeutics and providing related research services, positioning itself within the pharmaceutical R&D value chain.
Average Trading Volume: 700,821
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.09B
For an in-depth examination of 4583 stock, go to TipRanks’ Overview page.